This look ahead at hematologic malignancies in 2017 focuses on new agents being studied for the treatment of acute leukemias, myelodysplastic syndromes, and chronic lymphocytic leukemia.
Guido Marcucci, MD
Advertisement
Articles by Guido Marcucci, MD
In this article we discuss the challenges and new advances in adult ALL, as well as our approach to the treatment of these patients.
We review here the state of the art of diagnosis and treatment of AML and provide insights into the emerging novel biomarkers and therapeutic agents that are anticipated to be useful for the implementation of personalized medicine in AML.
Advertisement
Latest Updated Articles
Acute Myeloid Leukemia: Biologic, Prognostic, and Therapeutic InsightsPublished: April 16th 2016 | Updated:
- Treatment of Acute Lymphoblastic Leukemia in Adults: Applying Lessons Learned in Children
Published: December 15th 2016 | Updated:
- Outlook for 2017: Acute Leukemias, MDS, and CLL
Published: December 26th 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
More Global Expertise and Talent Are Needed to Administer Cell Therapies
2
FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset
3
Adaptive Treatment and Other Advances May Drive Radiotherapy Field Forward
4
Examining the Full Scope of Future Advancements in Radiation Oncology
5
